Mackenzie Financial
KRYS icon

Mackenzie Financial’s Krystal Biotech KRYS Stock Holding History

Mackenzie Financial’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,554
Closed -$384K – 1595
2025
Q4 		$384K Sell
1,554
-43
-3% -$9.05K ﹤0.01% 1296
2025
Q3 		$282K Hold
1,597
– – ﹤0.01% 1446
2025
Q2 		$220K Buy
1,597
+65
+4% +$9.55K ﹤0.01% 1519
2025
Q1 		$276K Hold
1,532
– – ﹤0.01% 1405
2024
Q4 		$240K Buy
1,532
+46
+3% +$8.16K ﹤0.01% 1479
2024
Q3 		$270K Buy
1,486
+129
+10% +$24.9K ﹤0.01% 1237
2024
Q2 		$249K Hold
1,357
– – ﹤0.01% 1257
2024
Q1 		$241K Buy
+1,357
New +$188K ﹤0.01% 1271

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mackenzie Financial's KRYS Position: Q1 2026 in Review

Mackenzie Financial sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 1,554 shares — an estimated $384K sold.

Mackenzie Financial first reported a position in KRYS in Q1 2024 and held it in 8 quarters. The position peaked at $384K in Q4 2025. 368 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Mackenzie Financial reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 1,554 Krystal Biotech shares in Q1 2026, an estimated $384K.
  • Mackenzie Financial first reported a position in Krystal Biotech in Q1 2024 and held it in 8 quarters.
  • Mackenzie Financial's Krystal Biotech position peaked at $384K in Q4 2025.
  • 368 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.